Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC): primary endpoint…
- A Trial In Patients With Advanced Cancer And Leukemia: Complete Statistical AnalysisIndependent statistical analysis of A Trial In Patients With Advanced Cancer And Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00878189).
- A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Trial of FANG™ Vaccine for Participants With Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Trial of FANG™ Vaccine for Participants With Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01309230).
- A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile: Complete Statistical AnalysisIndependent statistical analysis of A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable…
- A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp: Complete Statistical AnalysisIndependent statistical analysis of A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic…
- A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC): Complete Statistical AnalysisIndependent statistical analysis of A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of…
- A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate…
- A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing’s Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A-PREDICTIndependent statistical analysis of A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- ABC-01Independent statistical analysis of ABC-01, a phase 1 study evaluating hydroxychloroquine with hormonal therapy in metastatic estrogen receptor-positive breast cancer progressing on hormonal therapy.
- ABC-02Independent statistical analysis of ABC-02, a phase 3 randomized trial evaluating gemcitabine with or without cisplatin in patients with unresectable locally advanced or metastatic biliary tract tumors.
- ABEMA Alone or in COMBO With MK-6482: Complete Statistical AnalysisIndependent statistical analysis of ABEMA Alone or in COMBO With MK-6482: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04627064).
- ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- ABY-029Independent statistical analysis of A Microdose Evaluation Study of ABY-029 in Recurrent Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02901925).
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Acceptance and Commitment Therapy for Chronic Pain in Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Acceptance and Commitment Therapy for Chronic Pain in Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03661840).
- ACCESSIndependent statistical analysis of ACCESS (Access for Cancer Caregivers for Education and Support for Shared Decision Making): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy: Complete Statistical AnalysisIndependent statistical analysis of Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- ACOSOG Z0011An educational statistical analysis of ACOSOG Z0011, a randomized phase 3 trial of lymph node removal in women with stage I or stage IIA breast cancer, including its design, endpoints, planned statistical…
- ACOSOG Z1071Independent statistical analysis of ACOSOG Z1071, a phase 2 diagnostic trial evaluating sentinel lymph node surgery after chemotherapy in women with stage II, stage IIIA, or stage IIIB breast cancer.
- ACT IIAn independent statistical analysis of ACT II, a randomized phase 3 trial of radiation therapy plus fluorouracil with or without additional chemotherapy in patients with primary anal cancer.
- Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp: Complete Statistical AnalysisIndependent statistical analysis of Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ACTS-GCAn independent statistical analysis of ACTS-GC, a phase 3 randomized trial evaluating TS-1 (S-1) after surgery for gastric cancer, including design, endpoints, planned statistical methods, and interpretation.
- Acupressure for Fatigue in Ovarian Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Acupressure for Fatigue in Ovarian Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03763838).
- ADAPTIndependent statistical analysis of Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer:…
- ADAPTSC+Independent statistical analysis of Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- ADAURAIndependent statistical analysis of the ADAURA phase 3 trial of AZD9291 versus placebo after complete tumour resection in stage IB-IIIA non-small cell lung carcinoma, including disease-free survival, overall survival, trial design, methodology,…
- ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN: Complete Statistical AnalysisIndependent statistical analysis of ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04639024).
- Addressing Cancer-Related Financial Toxicity in North Carolina Oncology Care Settings: Complete Statistical AnalysisIndependent statistical analysis of Addressing Cancer-Related Financial Toxicity in North Carolina Oncology Care Settings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04931251).
- Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study: Complete Statistical AnalysisIndependent statistical analysis of Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03624972).
- ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing’s Sarcoma, and Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer: primary endpoint results, effect estimate…
- Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation: Complete Statistical AnalysisIndependent statistical analysis of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01206296).
- Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences: Complete Statistical AnalysisIndependent statistical analysis of Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences: primary endpoint results, effect estimate with confidence…
- AEGEANIndependent statistical analysis of the phase 3 AEGEAN trial of neoadjuvant/adjuvant durvalumab for patients with resectable non-small cell lung cancer, covering trial design, pCR, event-free survival, statistical methodology, planned analysis, and interpretation.
- AFEQTIndependent statistical analysis of Colorectal Cancer Metastatic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01670721).
- AFFIRMComplete statistical analysis of the AFFIRM phase 3 trial of enzalutamide versus placebo in patients with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, including overall survival, secondary time-to-event endpoints, response measures,…
- Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Aflibercept for Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Aflibercept for Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00437034).